|Table of Contents|

The efficacy of recombinant interleukin-2 peritumoral injection on local tumor responsiveness and its effect on subsquent symptomatic anxiety improvement

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 24
Page:
4649-4653
Research Field:
Publishing date:

Info

Title:
The efficacy of recombinant interleukin-2 peritumoral injection on local tumor responsiveness and its effect on subsquent symptomatic anxiety improvement
Author(s):
RONG Xiumei; XU Dazhao; HUO Feifei; GENG Zhenying; LIN Ping; ZHAO Haiyang; WU Tiecheng; WANG Xiaoli
Department of Oncology,Beijing Zhongguancun Hospital（Zhongguancun Hospital,Chinese Academy of Sciences）,Beijing 100190，China.
Keywords:
recombinant interleukin-2; superficial tumors; curative effect; anxiety
PACS:
R730.5
DOI:
10.3969/j.issn.1672-4992.2024.24.011
Abstract:
Objective:To analyze the disease control effect of recombinant interleukin-2 (rIL-2) via peritumoral injected on superficial tumors which were associated with systematic improvement on life quality,anxiety and depression.Methods:24 patients with average age of 75.5 years old who were not eligiable for standard chemotherapy were enrolled with superficial tumors treated in our hospital were retrospectively studied January 2022 to February 2024.rIL-2 was administrated via peritumoral injectived on superficial tumors with an initial dose of 500 000 IU/m2 for conseutive three weeks followed by escalation up to 1 000 000 IU/m2 at the fifth to seventh weeks.The tumor size,the score of quality of life(QOL),self-rating anxiety scale(SAS),self-rating depressions scale(SDS) were recorded.Results:The disease control rate(DcR) of patients included was 91.7% after therapy of rIL- concurrent with the decreased tumor size (P>0.05).The score of QoL was improved(P<0.05) with contrast to lowered severity of anxiety and depression (P<0.05) when the dose of rIL-2 enhanced from 500 000 IU/m2 to 1 000 000 IU/m2.Conclusion:The alternative administration of rIL-2 peritumoral injected on superficial tumors as minicking systemic anti-cancer therapy could improve the quality of life as effective supporting care for those aged patients.

References:

［1］CHOUDHRY H,HELMI N,ABDULAAL WH,et al.Prospects of IL-2 in cancer immunotherapy［J］.Biomed Res Int,2018,2018:9056173.
［2］KIM JH,LEE KJ,LEE SW.Cancer immunotherapy with T-cell targeting cytokines:IL-2 and IL-7［J］.BMB Rep,2021,54(1):21-30.
［3］LIN A.Cancer immunotherapy:an evolving paradigm［J］.J Zhejiang Univ Sci B,2022,23(10):791-792.
［4］WANG HB,BORLONGAN M,HEMMINKI A,et al.Viral vectors expressing interleukin 2 for cancer immunotherapy［J］.Human Gene Therapy,2023,34(17-18):878-895.
［5］MORTARA L,BALZA E,BRUNO A,et al.Anti-cancer therapies employing IL-2 cytokine tumor targeting:Contribution of innate,adaptive and immunosuppressive cells in the anti-tumor efficacy［J］.Front Immunol,2018,9:2905.
［6］AGHBASH PS,RASIZADEH R,YARI AH,et al.Interleukin-2 and oncolytic virotherapy:A new perspective in cancer therapy［J］.Anticancer Agents Med Chem,2023,23(18):2008-2026.
［7］KO B,TAKEBE N,ANDREWS O,et al.Rethinking oncologic treatment strategies with interleukin-2［J］.Cells,2023,12(9):1316.
［8］RAFEI-SHAMSABADI D,LEHR S,BEHRENS M,et al.Additive intralesional interleukin-2 improves progression-free survival in a distinct subgroup of melanoma patients with prior progression under immunotherapy［J］.Cancers,2022,14(3):540.
［9］TANG F,ZhONG Q,YANG Z,et al.Low-dose cyclophosphamide combined with IL-2 inhibits tumor growth by decreasing regulatory T cells and increasing CD8+ T cells and natural killer cells in mice［J］.Immunobiology,2022,227(3):152212.
［10］柯瑶，张琪，王娜.晚期乳腺癌患者经TP方案治疗后TNF-α、IL-6和IL-2 水平变化及对预后的预测价值［J］.分子诊断与治疗杂志,2022,14(9):1468-1472. KE Yao,ZHANG Qi,WANG Na.Changes of TNF-α,IL-6 and IL-2 levels in patients with advanced breast cancer treated with TP regimen and their prognostic value［J］.Journal of Molecular Diagnosis and Treatment,2022,14(9):1468-1472.
［11］NAKHLBAND A,FARAHZADI R,SAEEDI N,et al.Bidirectional relations between anxiety,depression,and cancer:A review［J］.Current Drug Targets,2023,24(2):118-130.
［12］GUI H,CHEN XL,LI LZ,et al.Psychological distress influences lung cancer:Advances and perspectives on the immune system and immunotherapy［J］.International Immunopharmacology,2023,121:110251.
［13］CHEN XY,WANG M,YU K,et al.Chronic stress-induced immune dysregulation in breast cancer:Implications of psychosocial factors［J］.Journal of Translational Internal Medicine,2023,11(3):226-233.
［14］FRATERMAN I,REIJERS ILM,DIMITRIADIS P,et al.Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma［J］.Nature Medicine,2023,29(12):3090-3099.
［15］HATHAWAY CA,TOWNSEND MK,CONEJO-GARCIA JR,et al.The relationship of lifetime history of depression on the ovarian tumor immune microenvironment［J］.Brain Behav Immun,2023,114:52-60.
［16］POLETTI S,ZANARDI R,MANDELLI A,et al.Low-dose interleukin 2 antidepressant potentiation in unipolar and bipolar depression: Safety,efficacy,and immunological biomarkers［J］.Brain Behav Immun,2024,118:52-68.
［17］AN E,LO C,HALES S,et al.Demoralization and death anxiety in advanced cancer［J］.Psychooncology,2018,27(11):2566-2572.
［18］雷婷.症状负担对老年癌症化疗患者失志综合征的作用路径研究［D］.福州：福建医科大学,2021. LEI Ting.Study on the pathway of symptom burden on dementia syndrome in elderly cancer chemotherapy patients［D］.Fuzhou:Fujian Medical University,2021.
［19］NORVILLE K,SKROMBOLAS D,FERRY SL,et al.A protease activatable interleukin-2 fusion protein engenders antitumor immune responses by interferon gamma-dependent and interferon gamma-independent mechanisms［J］.J Interferon Cytokine Res,2022,42(7):316-328.
［20］KONDOH N,MIZUNO-KAMIYA M.The role of immune modulatory cytokines in the tumor microenvironments of head and neck squamous cell carcinomas［J］.Cancers(Basel),2022,14(12):2884.
［21］KAPTEIN P,JACOBERGER-FOISSAC C,DIMITRIADIS P,et al.Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors［J］.Science Translational Medicine,2022,14(642):9779.
［22］POURMALEKI M,JONES CJ,ARIYAN CE,et al.Tumor MHC class I expression associates with intralesional IL2 response in melanoma［J］.Cancer Immunology Research,2022,10(3):303-313.
［23］曾益新.肿瘤学（第3版）［M］.北京:人民卫生出版社,2012: 533-534. ZENG Yixin.Oncology(3rd edition)［M］.Beijing:People's Health Publishing House,2012:533-534.
［24］ MAHMOUDPOUR SH,JANKOWSKI M,VALERIO L,et al.Safety of low-dose subcutaneous recombinant interleukin-2:systematic review and meta-analysis of randomized controlled trials［J］.Sci Rep,2019,9(1):7145.
［25］ZHOU Y,QUAN G,LIU Y,et al.The application of interleukin-2 family cytokines in tumor immunotherapy research［J］.Front Immunol,2023,14:1090311.

Memo

Memo:
-
Last Update: 1900-01-01